Abar, Farnoush
| Alumkal, Joshi
| Bagby, Grover C.
| Bascom, Paul
| Beer, Tomasz M.
| Chen, Andy
| Chui, Stephen
| Dao, Kim-Hien
| Deininger, Michael WN
| DeLoughery, Thomas
| Druker, Brian J.
| Fleming, William H.
| Fromme, Erik
| Gajewski, James
| Gramza, Ann
| Greenberg, Daniel
| Hayes-Lattin, Brandon
| Heinrich, Michael C.
| Kemmer, Kathleen
| Kovacsovics, Tibor
| Lopez, Charles D.
| Luoh, Shiuh-Wen
| Mauro, Michael J.
| Maziarz, Richard
| Meyers, Gabrielle
| Okada, Craig
| Qian, David
| Ryan, Christopher W.
| Sandler, Alan B.
| Skach, William
| Spurgeon, Stephen
| Streeter, Philip
| Taylor, Jason
| Thomas, Charles
| | Vaccaro, Gina | |
|
|
|
 |
|
|
Our Faculty
Alan B. Sandler, M.D.
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Specialty: Lung & Thoracic Cancer
Administrative Office: 503-494-5586
Clinic: 503-494-6594
Accepting Patients: Yes
Biography Alan Sandler is a Professor of Medicine in the Division of Hematology & Medical Oncology, Department of Medicine, at Oregon Health & Science University in Portland, Oregon where he also serves as the Division Chief of the Hematology & Medical Oncology Division, and is the DeArmond Chair for Clinical Cancer Research. After earning a B.S. in Pharmacy (cum laude) at the University of Toledo in Ohio and an M.D. at Rush Medical College in Chicago, Dr. Sandler completed an internship and residency in Internal Medicine at Yale-New Haven Hospital and a Fellowship in Medical Oncology at the Yale University School of Medicine in New Haven, Connecticut. His academic honors include membership in Alpha Omega Alpha and Rho Chi, the medical and pharmaceutical honor societies. Dr. Sandler is a member of the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group, where he serves as the Co-Chair of the Thoracic Committee. He is principal investigator or co-principal investigator of several therapeutic clinical trials that evaluate the activity of chemotherapeutic agents and/or combined-modality therapies in both small and non-small cell lung cancer as well as sarcoma. Dr. Sandler serves on the Editorial Boards of Clinical Lung Cancer and the Japanese Journal of Clinical Oncology, and is a reviewer for several journals including The New England Journal of Medicine, Journal of Clinical Oncology, Cancer Investigations, Cancer, the British Journal of Cancer, and European Respiratory Journal. Dr. Sandler is the author or co-author of more than 200 published articles, book chapters, reviews, and abstracts involving the pharmacology and clinical activity of chemotherapy and novel targeted agents, with a particular emphasis on lung cancer.
Appointments
- 1992-1998: Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Indiana University Medical Center
- 1998-2000: Associate Professor, Department of Medicine, Division of Hematology/Oncology, Indiana University Medical Center
- 2000-2008: Associate Professor, Division of Hematology/Oncology, Vanderbilt University Medical Center
- 2000-2008: Medical Director, Thoracic Oncology, Vanderbilt University Medical Center
- 2000-2008: Medical Director, Vanderbilt-Ingram Cancer Center Affiliate Network (VICCAN)
- 2005-2008: Co-Director, Center for Management Research in Healthcare, Vanderbilt University
- 2008-present: Professor of Medicine, School of Medicine, Hematology & Medical Oncology, Oregon Health & Science University
- 2008-present: Division Chief, Hematology & Medical Oncology, Oregon Health & Science University
- 2008-present: DeArmond Chair, Clinical Cancer Research, Oregon Health & Science University
Personal
Dr. Sandler is married, and has three children. He is a die-hard Cleveland sports fan, Bruce Springsteen fan, and avid golfer (but regrettably not a very good one).
|
|
Professional Education and Training
- 1980 - Bachelor of Science in Pharmacy (Cum Laude), University of Toledo, Toledo, OH
- 1987 - Doctor of Medicine, Rush Medical College, Chicago, IL
Post-Graduate Education
- 1987-1989: Internal Medicine Internship, Yale-New Haven Hospital, New Haven, CT
- 1987-1989: Internal Medicine Residency, Yale-New Haven Hospital, New Haven, CT
- 1989-1992: Medical Oncology Fellowship, Yale University School of Medicine, New Haven, CT
Certifications
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
|  | | |
Selected Publications
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel plus Carboplatin with or without Bevacizumab in Advanced Non-squamous Non-small Cell Lung Cancer: A Randomized Study of the Eastern Cooperative Oncology Group. N Engl J Med 355:2542-2550, 2006.
- Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart LL, Melnyk O, Ramies D, Lin M, Sandler AB. Phase II Study of Efficacy and Safety of Bevacizumab (Avastin) in Combination with Chemotherapy or Erlotinib (Tarceva) Compared with Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lunc Cancer. J Clin Oncol 25:4743-4750, 2007.
- DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES (2ND EDITION): Mark A. Socinski, Richard Cromwell, Thomas E. Hensing, Corey J. Langer, Stage IV: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest, Sep 2007; 132:277S-289S.
-
Johnson DH, Blot WJ, Carbone DP, Gonzalez A, Hallahan D, massion PP, Putnam JB, Sandler AB. Cancer of the Lung: NSCLC and SCLC. Clinical Oncology (TBA). 4th Edition. Editors: Abeloff M, et al. - Horn L, Sandler A. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 8:S68-73, 2007.
|
|
